Origin of sporadic late-onset hereditary ATTR Val30Met amyloidosis in Japan

References

• Sipe JD, Benson MD, Buxbaum JN, et al. Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines. Amyloid. 2016;23:209–213.
   PubMed Web of Science ®Google Scholar
• Planté-Bordeneuve V, Said G. Familial amyloid polyneuropathy. Lancet Neurol. 2011;10:1086–1097.
   PubMed Web of Science ®Google Scholar
• Benson MD, Kincaid JC. The molecular biology and clinical features of amyloid neuropathy. Muscle Nerve. 2007;36:411–423.
   PubMed Web of Science ®Google Scholar
• Ando Y, Coelho T, Berk JL, et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis. 2013;8:31–46.
   PubMed Web of Science ®Google Scholar
• Ando Y, Nakamura M, Araki S. Transthyretin-related familial amyloidotic polyneuropathy. Arch Neurol. 2005;62:1057–1062.
   PubMed Web of Science ®Google Scholar
• Misu K, Hattori N, Nagamatsu M, et al. Late-onset familial amyloidotic polyneuropathy type I (Met 30 transthyretin mutation) unrelated to endemic focus in Japan: clinicopathologic and genetic features. Brain. 1999;122:1951–1962.
   PubMed Web of Science ®Google Scholar
• Sousa A, Coelho T, Barros J, et al. Genetic epidemiology of familial amyloidotic polyneuropathy (FAP)-type I in Póvoa do Varzim and Vila do Conde (north of Portugal). Am J Med Genet. 1995;60:512–521.
   PubMed Web of Science ®Google Scholar
• Holmgren G, Costa PM, Andersson C, et al. Geographical distribution of TTR met30 carriers in northern Sweden: discrepancy between carrier frequency and prevalence rate. J Med Genet. 1994;31:351–354.
   PubMed Web of Science ®Google Scholar
• Coelho T, Maurer MS, Suhr OB. THAOS - The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis. Curr Med Res Opin. 2013;29:63–76.
   PubMed Web of Science ®Google Scholar
• Araki S, Mawatari S, Ohta M, et al. Polyneuritic amyloidosis in a Japanese family. Arch Neurol. 1968;18:593–602.
   PubMed Web of Science ®Google Scholar
• Ikeda S, Hanyu N, Hongo M, et al. Hereditary generalized amyloidosis with polyneuropathy. Clinicopathological Study of 65 Japanese Patients. Brain. 1987;110:315–337.
   PubMed Web of Science ®Google Scholar
• Koike H, Misu K, Ikeda S, et al. Type I (transthyretin Met30) familial amyloid polyneuropathy in Japan: early- vs late-onset form. Arch Neurol. 2002;59:1771–1776.
   PubMed Web of Science ®Google Scholar
• Koike H, Tanaka F, Hashimoto R, et al. Natural history of transthyretin Val30Met familial amyloid polyneuropathy: analysis of late-onset cases from non-endemic areas. J Neurol Neurosurg Psychiatry. 2012;83:152–158.
   PubMed Web of Science ®Google Scholar
• Yamashita T, Ueda M, Misumi Y, et al. Genetic and clinical characteristics of hereditary transthyretin amyloidosis in endemic and non-endemic areas: experience from a single-referral center in Japan. J Neurol. 2018;265:134–140.
   PubMed Web of Science ®Google Scholar
• Planté-Bordeneuve V, Ferreira A, Lalu T, et al. Diagnostic pitfalls in sporadic transthyretin familial amyloid polyneuropathy (TTR-FAP). Neurology. 2007;69:693–698.
   PubMed Web of Science ®Google Scholar
• Koike H, Hashimoto R, Tomita M, et al. Diagnosis of sporadic transthyretin Val30Met familial amyloid polyneuropathy: a practical analysis. Amyloid. 2011;18:53–62.
   PubMed Web of Science ®Google Scholar
• Lozeron P, Mariani LL, Dodet P, et al. Transthyretin amyloid polyneuropathies mimicking a demyelinating polyneuropathy. Neurology. 2018;91:e143–e152.
   PubMed Web of Science ®Google Scholar
• Yoshioka A, Yamaya Y, Saiki S, et al. A case of familial amyloid polyneuropathy homozygous for the transthyretin Val30Met gene with motor-dominant sensorimotor polyneuropathy and unusual sural nerve pathological findings. Arch Neurol. 2001;58:1914–1918.
   PubMedGoogle Scholar
• Holmgren G, Bergström S, Drugge U, et al. Homozygosity for the transthyretin-Met30-gene in seven individuals with familial amyloidosis with polyneuropathy detected by restriction enzyme analysis of amplified genomic DNA sequences. Clin Genet. 2008;41:39–41.
   Google Scholar
• Tojo K, Sekijima Y, Machida K, et al. Amyloidogenic transthyretin Val30Met homozygote showing unusually early-onset familial amyloid polyneuropathy. Muscle Nerve. 2008;37:796–803.
   PubMed Web of Science ®Google Scholar
• Tasaki M, Ueda M, Obayashi K, et al. Effect of age and sex differences on wild-type transthyretin amyloid formation in familial amyloidotic polyneuropathy: a proteomic approach. Int J Cardiol. 2013;170:69–74.
   PubMed Web of Science ®Google Scholar
• Ohmori H, Ando Y, Makita Y, et al. Common origin of the Val30Met mutation responsible for the amyloidogenic transthyretin type of familial amyloidotic polyneuropathy. J Med Genet. 2004;41:e51.
   PubMed Web of Science ®Google Scholar
• Olsson M, Norgren N, Obayashi K, et al. A possible role for miRNA silencing in disease phenotype variation in Swedish transthyretin V30M carriers. BMC Med Genet. 2010;11:130.
   PubMed Web of Science ®Google Scholar
• Soares ML, Coelho T, Sousa A, et al. Haplotypes and DNA sequence variation within and surrounding the transthyretin gene: genotype-phenotype correlations in familial amyloid polyneuropathy (V30M) in Portugal and Sweden. Eur J Hum Genet. 2004;12:225–237.
   PubMed Web of Science ®Google Scholar
• Norgren N, Hellman U, Ericzon BG, et al. Allele specific expression of the transthyretin gene in Swedish patients with hereditary transthyretin amyloidosis (ATTR V30M) is similar between the two alleles. PLoS One. 2012;7:e49981.
   PubMed Web of Science ®Google Scholar
• Soares ML, Coelho T, Sousa A, et al. Susceptibility and modifier genes in Portuguese transthyretin V30M amyloid polyneuropathy: complexity in a single-gene disease. Hum Mol Genet. 2005;14:543–553.
   PubMed Web of Science ®Google Scholar
• Dardiotis E, Koutsou P, Zamba-Papanicolaou E, et al. Complement C1Q polymorphisms modulate onset in familial amyloidotic polyneuropathy TTR Val30Met. J Neurol Sci. 2009;284:158–162.
   PubMed Web of Science ®Google Scholar
• Santos D, Coelho T, Alves-Ferreira M, et al. Familial amyloid polyneuropathy in Portugal: new genes modulating age-at-onset. Ann Clin Transl Neurol. 2017;4:98–105.
   PubMed Web of Science ®Google Scholar
• Yamamoto K, Ikeda S, Hanyu N, et al. A pedigree analysis with minimised ascertainment bias shows anticipation in Met30-transthyretin related familial amyloid polyneuropathy. J Med Genet. 1998;35:23–30.
   PubMed Web of Science ®Google Scholar
• Hellman U, Alarcon F, Lundgren HE, et al. Heterogeneity of penetrance in familial amyloid polyneuropathy, ATTR Val30Met, in the Swedish population. Amyloid. 2008;15:181–186.
   PubMed Web of Science ®Google Scholar
• Lemos C, Coelho T, Alves-Ferreira M, et al. Overcoming artefact: anticipation in 284 Portuguese kindreds with familial amyloid polyneuropathy (FAP) ATTRV30M. J Neurol Neurosurg Psychiatry. 2014;85:326–330.
   PubMed Web of Science ®Google Scholar
• Olsson M, Hellman U, Planté-Bordeneuve V, et al. Mitochondrial haplogroup is associated with the phenotype of familial amyloidosis with polyneuropathy in Swedish and French patients. Clin Genet. 2009;75:163–168.
   PubMed Web of Science ®Google Scholar
• Bonaïti B, Olsson M, Hellman U, et al. TTR familial amyloid polyneuropathy: does a mitochondrial polymorphism entirely explain the parent-of-origin difference in penetrance? Eur J Hum Genet. 2010;18:948–952.
   PubMed Web of Science ®Google Scholar
• Santos D, Santos MJ, Alves-Ferreira M, et al. mtDNA copy number associated with age of onset in familial amyloid polyneuropathy. J Neurol Neurosurg Psychiatry. 2018;89:300–304.
   PubMed Web of Science ®Google Scholar
• Cooper DN, Krawczak M. The mutational spectrum of single base-pair substitutions causing human genetic diseases: pattern and prediction. Hum Genet. 1990;85:55–74.
   PubMed Web of Science ®Google Scholar
• Zaros C, Genin E, Hellman U, et al. On the origin of the transthyretin Val30Met familial amyloid polyneuropathy. Ann Hum Genet. 2008;72:478–484.
   PubMed Web of Science ®Google Scholar
• Iorio A, De Angelis F, Di Girolamo M, et al. Most recent common ancestor of TTR Val30Met mutation in Italian population and its potential role in genotype-phenotype correlation. Amyloid. 2015;22:73–78.
   PubMed Web of Science ®Google Scholar
• Bergström J, Gustavsson A, Hellman U, et al. Amyloid deposits in transthyretin-derived amyloidosis: cleaved transthyretin is associated with distinct amyloid morphology. J Pathol. 2005;206:224–232.
   PubMed Web of Science ®Google Scholar
• Ihse E, Ybo A, Suhr O, et al. Amyloid fibril composition is related to the phenotype of hereditary transthyretin V30M amyloidosis. J Pathol. 2008;216:253–261.
   PubMed Web of Science ®Google Scholar
• Oshima T, Kawahara S, Ueda M, et al. Changes in pathological and biochemical findings of systemic tissue sites in familial amyloid polyneuropathy more than 10 years after liver transplantation. J Neurol Neurosurg Psychiatry. 2014;85:740–746.
   PubMed Web of Science ®Google Scholar
• Marcoux J, Mangione PP, Porcari R, et al. A novel mechano-enzymatic cleavage mechanism underlies transthyretin amyloidogenesis. EMBO Mol Med. 2015;7:1337–1349.
   PubMed Web of Science ®Google Scholar
• Suhr OB, Lundgren E, Westermark P. One mutation, two distinct disease variants: unravelling the impact of transthyretin amyloid fibril composition. J Intern Med. 2017;281:337–347.
   PubMed Web of Science ®Google Scholar